Advances in Antiviral Drug Design, 4

افزودن به بوکمارک اشتراک گذاری 0 دیدگاه کاربران 5 (0)

مشارکت: عنوان و توضیح کوتاه هر کتاب را ترجمه کنید این ترجمه بعد از تایید با نام شما در سایت نمایش داده خواهد شد.

ترجمه این کتاب مشاهده همه کتاب های ترجمه نشده

از خودتان درباره کتاب توضیح کوتاهی بنویسید

The fourth volume of "Advances in Antiviral Drug Design" is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.
First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.
Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.
Third, as all currently available PIs can be described as "peptidomimetic," and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.
Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.
Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone "upstream" in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.
Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.
The six topics covered in this fourth volume of "Advances in Antiviral Drug Design" are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.

لغو

گزارش تخلف

مغایرت عنوان کتاب با توضیحات و تصویر جلد
عدم رعایت حقوق نشر طبق قوانین جمهوری اسلامی ایران
محتوای مستهجن
توهین به قومیتها و محتوای نژادپرستی
توهین به اقیلیتهای مذهبی
اهانت به مقامات سیاسی و مذهبی
اشاعه ی کودک آزاری
سایر موارد

بستن

فرمت کتاب

ebook

زبان

english

تاریخ انتشار

2003

نویسنده

E. De Clercq

ناشر

Elsevier Science

شابک

9780444506023

20,000 تومان

خرید کتاب مطالعه نمونه درخواست ترجمه کتاب

خرید کتاب Advances in Antiviral Drug Design, 4

Advances in Antiviral Drug Design, 4

گزارش تخلف

فرمت کتاب

ebook

زبان

english

تاریخ انتشار

2003

نویسنده

ناشر

شابک

کتاب های مرتبط

Advances in Antiviral Drug Design, 4

Structure-activity relationship studies in drug development by NMR spectroscopy. [Volume 1] [electronic resource]

3D Qsar in Drug Design

The Process of New Drug Discovery and Development

Pharmaceutical Isothermal Calorimetry

Gene Profiles in Drug Design

Chirality in Drug Design and Development

Functional Protein Microarrays in Drug Discovery

Advanced Drug Formulation Design to Optimize Therapeutic Outcomes

Handbook of Assay Development in Drug Discovery

Protein Folding and Drug Design

Adaptive Systems in Drug Design

Phosphatase Modulators

Chemometric Methods in Molecular Design, Volume 2

Incentivos a la I+d+i de Medicamentos

Small Molecule -- Protein Interactions

The Practice of Medicinal Chemistry

PEGylated protein drugs : basic science and clinical applications

Influenza virus sialidase-- a drug discovery target

Quantitative Structure - Activity Relationship

Mutifaceted Roles of Crystallography in Modern Drug Discovery

دیدگاه کاربران